Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.

Published online

Journal Article

We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted HRs for DFS and OS censored at five years (in an attempt to minimize misclassification from noncancer death) were 0.61 (95% CI = 0.36 to 1.04) and 0.48 (95% CI = 0.23 to 0.99). Among 843 eligible patients, those who used COX-2 inhibitors had multivariable HRs for RFS, DFS, and OS of 0.53 (95% CI = 0.27 to 1.04), 0.60 (95% CI = 0.33 to 1.08), and 0.50 (95% CI = 0.23 to 1.07), and HRs of 0.47 (95% CI = 0.24 to 0.91) and 0.26 (95% CI = 0.08 to 0.81) for DFS and OS censored at five years. Aspirin and COX-2 inhibitor use may be associated with improved outcomes in stage III colon cancer patients.

Full Text

Duke Authors

Cited Authors

  • Ng, K; Meyerhardt, JA; Chan, AT; Sato, K; Chan, JA; Niedzwiecki, D; Saltz, LB; Mayer, RJ; Benson, AB; Schaefer, PL; Whittom, R; Hantel, A; Goldberg, RM; Venook, AP; Ogino, S; Giovannucci, EL; Fuchs, CS

Published Date

  • January 2015

Published In

Volume / Issue

  • 107 / 1

Start / End Page

  • 345 -

PubMed ID

  • 25432409

Pubmed Central ID

  • 25432409

Electronic International Standard Serial Number (EISSN)

  • 1460-2105

Digital Object Identifier (DOI)

  • 10.1093/jnci/dju345

Language

  • eng

Conference Location

  • United States